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Tumor necrosis factor-α (TNF-α) plays an essential role in the regulation of bone homeosta-
sis in several chronic immune and inflammatory joint diseases, where inhibition of TNF
has led to significant clinical improvement. However, TNF-activated pathways and mecha-
nisms involved in bone remodeling remain unclear. So far,TNF-α was known as an inhibitor
of osteoblast differentiation and an activator of osteoclastogenesis. Recent contradictory
findings indicated that TNF-α can also activate osteoblastogenesis. The paradoxical role of
TNF-α in bone homeostasis seems to depend on the concentration and the differentiation
state of the cell type used as well as on the exposure time.This review aims to summarize
the recent contradictory findings on the regulation of bone homeostasis by TNF-α at the
isolated cell, whole bone, and whole body levels. In addition, the involvement of TNF-α
in the bone remodeling imbalance is observed in inflammatory joint diseases including
rheumatoid arthritis and ankylosing spondylitis, which are associated with bone destruc-
tion and ectopic calcified matrix formation, respectively. Both diseases are associated with
systemic/vertebral osteoporosis.
Keywords: TNF-α, bone homeostasis, osteoblast, osteoclast, rheumatoid arthritis, ankylosing spondylitis,
osteoporosis
INTRODUCTION
Tumor necrosis factor-α (TNF-α) is one of the several pro-
inflammatory cytokines involved in bone remodeling. Classically,
TNF-α plays a major role in the regulation of bone homeostasis
by stimulating osteoclastogenesis and inhibiting osteoblast (OB)
function. It is also involved in the pathogenesis of chronic inflam-
mation in both mouse and human models. Based on these obser-
vations, treatments of several chronic inflammatory diseases such
as Crohn’s disease, ulcerative colitis, and psoriasis target TNF-α.
TNF-α is also associated with the pathogenesis of inflammatory
joint diseases including rheumatoid arthritis (RA), which is char-
acterized by massive juxta-articular bone destruction, and anky-
losing spondylitis (AS), which is characterized by simultaneous
bone destruction and excessive formation, respectively. However,
opposite findings suggest that TNF-α may also induce osteogenic
differentiation. This review summarizes the classical and para-
doxical effects of TNF-α on bone homeostasis by focusing on
osteoblastogenesis and osteoclastogenesis.
TNF-α AND ITS SIGNALING PATHWAYS
The immune response is modulated by several inflammatory
cytokines including TNF-α. TNF-α acts through several path-
ways including the activation of nuclear factor kappa-B (NF-κB)
involved in inflammation and apoptosis (1). TNF-α is produced
mainly by monocytes, but can also be secreted by many other cell
types (1–3). It is produced as a transmembrane protein (mTNF-
α) that is subsequently cleaved by the TNF-α converting enzyme
(TACE) to a soluble form (sTNF-α) (4). Both types are biologi-
cally active and bind as a trimer to either TNF receptors TNFR1
(also known as TNFRSF1A or p55) or to TNFR2 (also known as
TNFRSF1B or p75).
Activation of TNFR1 death domain initiates the apoptotic sig-
naling through the activation of several factors such as caspase and
NF-κB resulting in transcription of pro-inflammatory cytokines,
chemokines, and anti-apoptotic molecules (5). Unlike TNFR1, the
cell expression of TNFR2 is far more limited and does not contain a
death domain. Its effects include T cell activation and proliferation
via signaling pathways that involve NF-κB, activator protein 1 (AP-
1), and the mitogen-activated protein kinases (MAPKs) (6). The
pro-inflammatory effects of this cytokine are well documented (7)
and are involved in many osteo-immunological diseases including
RA and AS (8).
In humans, TNF-α antagonists are clearly effective in a large
number of conditions, as first shown in patients with RA (9,
10). However, incidents of lupus-like syndrome and skin lesions
have been reported in patients receiving anti-TNF therapies (11).
The cellular and molecular mechanisms underlying the TNF-α-
mediated pro-inflammatory effects and the occasionally paradox-
ical effects of TNF-α antagonists in chronic inflammatory diseases
remain incompletely understood (10). This also applies to bone
biology.
BONE BIOLOGY
Bone structure is affected by several paracrine and endocrine fac-
tors including mechanical abrasion and serum electrolyte levels
such as calcium and phosphorus. This remodeling is regulated
by several cells such as osteoclasts (OCs), OBs, and osteocytes
(OYs) (12). This continuous remodeling prevents and removes
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fatigue-related micro-damage and allows adaptation of the bone
mass and structure. The number and activity of OCs and OBs are
determined by a multitude of factors such as hormones, cytokines,
and locally produced signaling molecules under the influence of
mechanical stimuli (13–15). Among these factors, TNF-α was
found to have great effects on both bone regulator cells, OBs
and OCs.
BIOLOGY OF OSTEOCLASTS
Osteoclasts are hematopoietic cells derived from the monocyte
lineage. They undergo a series of differentiation steps to become
mature bone-resorbing cells. Intracellular signaling cascade of
transcriptional regulation of osteoclast-specific genes is activated
by macrophage-colony-stimulating factor (M-CSF) and recep-
tor activator of nuclear factor kappa-B ligand (RANKL) (16)
(Figure 1). Upon differentiation, OC precursor cells express
strongly RANK, the receptor for RANKL.
BIOLOGY OF OSTEOBLASTS
Osteoblasts are derived from pluripotent stem cells called “mes-
enchymal stem cells (MSCs)” capable of differentiating into
adipocytes, chondrocytes, fibroblasts, skeletal muscle cells, and
tendon cells (17). A number of factors can stimulate the differ-
entiation toward an osteoblastic direction. The first step includes
the proliferation of osteoprogenitors leading to the production of
proteins such as histones, fibronectin, and type I collagen. Sub-
sequently, osteogenic matrix is formed through the expression
of genes responsible for the production of alkaline phosphatase
(ALP), bone sialoprotein, and type I collagen. Finally, extracellular
matrix is mineralized by activation of genes involved in the release
of osteocalcin (OCN), osteopontin, and collagenase. This complex
cascade of gene expression and cellular differentiation is orches-
trated by several transcription factors including the runt-related
transcription factor-2 (Runx2) and surface expression of RANKL
(Figure 2A).
BIOLOGY OF OSTEOCYTES
Osteocytes are derived from MSCs through OB differentiation.
They are located within the bone matrix and represent 90–95%
of all bone cells in adults (18). In addition, they have the longest
life span among bone cells, up to decades, within their mineral-
ized environment (19). OYs are involved in the dynamics of bone
structure through expression of different markers that are released
during OB-to-OY ontogeny. In addition, OYs affect the function
of other organs such as phosphate transport in kidney (20). Fur-
thermore, OYs are now known to be the principal sensors for
mechanical loading of bone. They translate the canalicular flow
resulting from bone loading into OCs and OBs recruiting signals
(21). Due to the high expression of RANKL by OYs, they have a
more significant contribution to osteoclastogenesis as compared
to OBs and bone MSCs (22, 23).
EFFECTS OF TNF-α ON ISOLATED CELLS
EFFECTS OF TNF-α ON OSTEOBLASTS
Previous in vitro studies have indicated an inhibitory effect
of TNF-α on OB differentiation (Table 1). This blockage of
osteogenic differentiation resulted from the inhibition of insulin-
like growth factor-1 (IGF-1), osterix (Osx also known as SP7), and
FIGURE 1 | Role ofTNF-α in osteoclast differentiation. Hematopoietic
stem cells differentiate along the myelo-monocytic pathway with M-CSF
stimulation. Differentiating cells continue along a trajectory toward the
osteoclast phenotype under the influence of RANKL, which signals through
the transcription factors AP-1 and NF-κB. In the presence of RANKL, various
pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1, cooperatively
orchestrate enhanced osteoclastogenesis. TNF-α signals via NF-κB and the
mitogen-activated protein kinases (MAPKs), and IL-6 via the JAK–STAT
pathway. The activation of osteoclasts with the inflammatory mechanisms
mentioned leads to exaggerated systemic and local bone loss. [AKT, protein
kinase B; CA2, carbonic anhydrase 2; CSK, cathepsin K; ERK, extracellular
signal-regulated kinase; IKK, IκB kinase; JAK, janus kinase; gp130,
glycoprotein 130; GRB2, growth factor receptor-bound protein 2; MITF,
microphthalmia-associated transcription factor; MMP, matrix
metalloproteinase; NFATc1, nuclear factor of activated T-cells, cytoplasmic
1; PI3K, phosphoinositide 3-kinase; SPI1, spleen focus forming virus (SFFV)
proviral integration oncogene spi1; STAT, signal transducer and activator of
transcription; TRAP, tartrate-resistant acid phosphatase].
Runx2 (24–26). The inhibition of Runx2 seemed to be mediated
by the TNF-induced up-regulation of Smurf1, a negative regulator
of OB differentiation that causes the degradation of Runx2 (27).
Moreover, TNF-α inhibited MSC differentiation into OBs via the
ubiquitin protein ligase Wwp1 in TNF transgenic mice express-
ing human TNF-α (28). Another human study demonstrated an
inhibitory effect of TNF-α on Runx2 and collagen expression.
However, an increase in alkaline phosphatase activity and matrix
mineralization was noted (29).
In full contrast with these findings, other murine and human
MSC studies have reported that TNF-α can also induce osteogenic
differentiation (Table 2). In three in vitro rodent models, low
concentrations of TNF-α increased osteogenic differentiation via
an up-regulation of Runx2, Osx, OCN, and ALP levels (38, 39).
Moreover, four human experimental models indicated a similar
osteogenic activity for TNF-α. In these models, osteogenic differ-
entiation was promoted via induction of BMP-2, Osx, Runx2, and
OCN (40–43). In addition, human models revealed that the dual
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FIGURE 2 |Tumor necrosis factor-α and its osteoblastogenesis
paradoxical effects. (A) Under normal condition, various receptors and
downstream signaling pathways can be activated in osteoblasts. The most
common ligands, receptors, and their signal transduction are represented
in black. Essential pathways involve bone morphogenetic proteins (BMPs)
and their receptors, acting via SMAD proteins to directly or
transcriptionally activate RUNX2 and its subsequent downstream cellular
events and the Wnt–frizzled pathway, which utilizes β-catenin for further
activities. Under inflammatory conditions, the release of pro-inflammatory
cytokines such as TNF-α and IL-6 leads to the inhibition of osteogenic
differentiation via several mechanisms (represented in green in the figure).
IL-6 inhibits mitogen-activated protein kinase (MAPK) activities by activated
signal transducers and activators of transcription (STAT). TNF-α activates
SMAD ubiquitination regulatory factor-1 (SMURF1) and SMURF2 leading
to the inhibition of SMADs. The pro-inflammatory cytokines also
up-regulate dickkopf-related protein 1 (DKK-1) and sclerostin (SOST), which
inhibit the Wnt–frizzled pathway, whereas many other osteoblast gene
products are down-regulated. (B)TNF-α can also favor osteogenic
differentiation via NF-κB by increasing expression of BMP-2, Osx, Runx2,
OCN, and Wnt pathway. [AP-1, activator protein 1; BMPR, BMP receptor;
ERK, extracellular signal-regulated kinase; FGF, fibroblast growth factor;
gp130, glycoprotein 130; IL-6R, IL-6 receptor; JAK, janus kinase; JNK, JUN
N-terminal kinase; LRP5-6, low-density lipoprotein receptor-related protein
5 or 6; Osx, osterix (Sp7); OPG, osteoprotegerin; ALP, alkaline
phosphatase; BSP, bone sialoprotein; OPN, osteopontin; OCN,
osteocalcin; p38, p38 MAPK].
role of TNF-αon osteogenic differentiation was directly dependent
on the concentration of TNF-α, the cell type, and the exposure
time (Table 2). Furthermore, a recent study showed that TNF-α
stimulated the expression of Wnt5a, which was directly associ-
ated with an increase in tissue non-specific alkaline phosphatase
(TNAP) levels and mineralization. This suggests an autocrine
stimulation of OB activity by Wnt5a in response to TNF in hMSCs
(44). This paradoxical effect of TNF-α in inhibiting or activating
osteoblastogenesis, lies in the differentiation stage of the respond-
ing cells. MSCs can differentiate into several lineages. At this early
stage, TNF-α binds its receptors and favors osteogenic differenti-
ation through activation of multiple signaling pathways, notably
NF-kB (40) (Figure 2B) (Table 2). On the other hand, TNF-α
inhibits osteoblastogenesis in the presence of pre-OB cells, which
are already on the differentiation process. This inhibition occurs
at different levels, where TNF-α induces DKK-1 expression that
inhibits Wnt pathway (45), or activates Smurf that inhibits BMP-2
pathway (31) (Figure 2A) (Table 1).
EFFECTS OF TNF-α ON OSTEOCYTES
Limited results are available on the effect of TNF-α on OYs,
which are known to be affected by the surrounding environ-
ment. TNF-α and interleukin-1 (IL-1), which increase with estro-
gen deficiency, can induce OYs apoptosis (48). In a fluid shear
stress study, in which the mechanical bone loading was mimic-
ked by applying pulsating fluid flow, the TNF-α-induced apop-
tosis observed in OYs was inhibited by mechanical loading.
However, this effect was not observed in OBs and periosteal
fibroblasts. Since apoptotic OYs attract OCs, these results sug-
gest a key role for OYs apoptosis in osteoclastic bone resorp-
tion during bone remodeling that is in part modulated by
TNF-α (49). Additionally, TNF-α was shown to inhibit the
increase in nitric oxide (NO) production and intracellular cal-
cium while strongly reducing F-actin content. This resulted in
a reduction of OYs stiffness and provided a possible mecha-
nism to explain the contribution of inflammation to loss of bone
mass (50).
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Table 1 | Overview of studies indicating aTNF-mediated inhibition of osteogenic differentiation.
Model TNF-α Effects Reference
Osteoblastic cell line and
MC3T3-E1 cells
Dose-dependent
IC50=0.6 ng/ml
TNF-α inhibits osteoblast differentiation via the inhibition of insulin-like growth
factor I (IGF-I) expression
(25)
Fetal calvaria precursor cells and
MC3T3-E1 (pre-OBs cell)
0.6 ng/ml TNF-α inhibits the expression of Runx2 (26)
Mice primary stromal cells 1–20 ng/ml TNF-α inhibits pre-osteoblast differentiation throughTNFR1 and by inhibiting Runx2 (24)
MSCs of mice 10 ng/ml TNFR1 mediates TNF inhibition of OBs differentiation independently of apoptosis (30)
TNF transgenic mice, C2Cl12 cells,
and 2T3 OBs precursor cells
2.5–7.5 ng/ml TNF-α promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2
in osteoblasts
(31)
Mouse myoblast cell line (C2C12) 10–100 ng/ml TNF-α inhibits BMP-induced osteoblast differentiation through activating
SAPK/JNK signaling
(32)
MC3T3-E1-clone 14 cells 10 ng/ml TNF-α represses BMP signaling by interfering with the DNA binding of SMADs
through the activation of NF-κB
(33)
hMSCs 0.1–1 ng/ml TNF-α inhibits Runx2 and collagen expression but increases ALP activity and
mineralization
(29)
C2C12 and calvaria cells 10 ng/ml Msx2 mediates the inhibitory action of TNF-α on osteoblast differentiation via
suppressing BMP-2
(34)
MSC from TNF transgenic mice 0.5µg/injection TNF-α inhibits MSC differentiation into OBs via the ubiquitin E3 ligase Wwp1 (28)
MC3T3-E1-clone 14 cells and
C3H10T1/2 cells
10 ng/ml TNF-α inhibits differentiation of OB progenitors via the homeobox protein Prx1,
which inhibits Osx and Runx2 transcription
(35)
C2C12 and primary mouse calvaria
cells
10 ng/ml TNF-α enhances the transcription of Smurf1 in an AP-1- and Runx2-dependent
manner leading to inhibition of OBs differentiation
(36)
Mouse ESC (osteo-mESC) and
primary OBs cells
– The pro-inflammatory cytokines IL-1β, TNF-α, and IFN-γ only reduce the formation
of bone nodules by primary OBs, and not by osteo-mESCs
(37)
EFFECTS OF TNF-α ON OSTEOCLASTS
The role of TNF-α as a stimulator of osteoclastogenesis is well
established (51–55). The expression of a number of transcrip-
tion factors, including NF-κB, is critical for osteoclastogenesis
(56, 57) (Figure 1). Early bone marrow progenitors embark on
a path toward pre-OCs or monocytes–macrophages under the
influence of M-CSF while TNF-α, IL-1, and RANKL promote a
progression toward the functional OCs phenotype. Thus, both
RANKL and TNF-α are not only required for, but also synergize
to induce osteoclastogenesis. The requirement for both TNF-α
and RANKL allows for a more precise control of OCs numbers
through a dual level of regulation. First, they affect the selective
signaling of the precursor cells via the two different receptors,
and subsequently their synergy further increases the activation of
NF-κB and AP-1 signaling. Furthermore, the effect of the pro-
inflammatory cytokines TNF-α, IL-17, IL-6, IL-1β, and IL-23 on
osteoclastogenesis in vitro demonstrated that they have specific
characteristic osteoclastogenic properties. However, they exhib-
ited osteoclastogenesis-related activity only in the presence of
permissive levels of RANKL. TNF-α appears to have osteoclas-
togenic properties in the early stage of osteoclastogenesis when
bone marrow-derived macrophages (BMMs) are at the stage of
osteoclast precursor cells (58).
EFFECTS OF TNF-α ONWHOLE BONE
These results on isolated cells need to be expanded to whole bone
studies in order to reproduce the cell–cell interactions between
bone specific cells and immune cells in the bone marrow. Only
a few studies have examined the effects of TNF alone or com-
bined to other cytokines such as IL-1 and IL-17 in ex vivo mod-
els or explants where both osteoclast and OB cells are present.
In a RA ex vivo model of bone resorption, an IL-4-mediated
inhibition of TNF-α levels corroborated with an inhibition in
bone resorption, manifested as a 35% increase in the mean total
bone area with IL-4 (59). Another study with RA-derived bone
explants showed that inhibition of TNF-α decreased inflamma-
tion as measured by levels of IL-6 and bone resorption markers.
These inhibitory effects were enhanced in combination with IL-
1 and IL-17 blockade (60). Histomorphometric analysis of bone
samples in patients with different diseases affecting bone such as
RA,Crohn’s disease, and bronchial asthma showed that eroded sur-
face over bone surface (ES/BS), a parameter of bone resorption,
was significantly increased in the context of high TNF-α levels
(61). On the contrary, one study showed that addition of TNF-α
to a cultured fetal mouse long bone explant induced NO produc-
tion resulting in suppression of osteoclast bone resorption (62).
These findings suggest a mixed effect of TNF-α on bone structure,
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Table 2 | Overview of studies indicating aTNF-mediated activation of osteogenic differentiation.
Model TNF-α Effects Reference
Human mesenchymal stem
cells
20 ng/ml TNF-α promotes osteogenic differentiation of hMSCs by triggering the NF-κB signaling
pathway, which in turn induces BMP-2 up-regulation resulting in the enhancement of
Runx2 and Osx expression
(40)
Rat mesenchymal stem cells 5–50 ng/ml TNF-α stimulates only at high dose the osteogenic differentiation of MSCs grown on
biodegradable polymeric microfiber scaffolds. However low TNF dose does the
opposite effect
(46)
Human adipose tissue-derived
mesenchymal stem cells
10 ng/ml NF-κB activation by TNF-α stimulates osteogenic differentiation of hADSCs by increasing
the expression of the phospholipids–lysophospholipid transacylase TAZ
(43)
Murine mesenchymal stem
cell line ST2
0.01–0.1 ng/ml TNF-α induces osteogenic differentiation via induction of Runx2 and Osx (38)
Murine models 1 ng/ml TNF-α promotes fracture repair by augmenting the recruitment and differentiation of
muscle-derived stromal cells
(39)
Adipose tissue-derived
mesenchymal stem cells
(ASCs)
1 ng/ml In a co-culture system of human OBs with ASCs, HOBs pre-treated with TNF-α for 24 h
induced a significantly greater osteogenic differentiation of ASCs than with the HOBs
without TNF-α treatment
(42)
Human adipose derived
stromal cells
10 ng/ml Recombinant human TNF-α promotes the in vitro human adipose derived stromal cells
transformation into osteoblasts via inducing Runx2 and Osx expression
(41)
Human mesenchymal stem
cells
1 ng/ml TNF-α increases the levels of Wnt5a, which in turn stimulates tissue-non-specific
alkaline phosphatase (TNAP) levels in an autocrine manner and increases mineralization
(44)
Human dental pulp stem cells
(DPSCs)
10 ng/ml TNF-α triggers osteogenic differentiation of human dental pulp stem cells via the NF-κB
signaling pathway
(47)
which corroborates with the paradoxical role of TNF-α observed
in vitro.
EFFECTS OF TNF-α IN VIVO
Tumor necrosis factor-α disrupts bone homeostasis by activating
osteoclastic resorption, inhibiting osteoblastic proliferation and
matrix synthesis, and activating TNF receptor-associated Factor-2
(TRAF-2). The latter activates NF-κB, AP-1, and MAPKs signaling
pathways, which leads to decreased bone formation.
In human TNF transgenic mice, TNF-α induced DKK-1, a reg-
ulatory molecule of the Wnt pathway, which led to impaired local
bone formation. In addition, blockade of DKK-1 interfered with
local bone resorption by reducing OCs numbers in the joints of
animal models with inflammatory arthritis (45, 63, 64). A recent
study of collagen-induced arthritis (CIA) in rats showed that TNF
inhibition did not significantly affect RANKL, TNF-α, and OPG
mRNA expression, which are linked to osteoclastogenesis, while
it promoted bone formation via suppression of DKK-1 expres-
sion. This was confirmed by histomorphometric analysis, which
demonstrated a significant increase in bone formation parameters
while the changes in bone destruction parameters were not signifi-
cant (63). Clinical trials in human RA confirmed the association of
TNF with arthritic bone destruction as observed in several human
TNF-α transgenic mouse models.
However, this observation was not clear in TNF-deficient
mouse models, due to insignificant reduction in the clini-
cal parameters of CIA and absence of major histological and
morphological abnormalities in the joints. Moreover, some mice
exhibited severe disease in the absence of TNF, suggesting the
contribution of other cytokines such as IL-1 (65–68).
TNF-α AND INFLAMMATORY JOINT DISEASES
Tumor necrosis factor-α has been associated with an increasing
number of chronic inflammatory diseases. Among these diseases,
the two most common inflammatory joint diseases RA and AS will
be discussed. RA causes massive destruction of juxta-articular and
systemic bone while AS leads to the concomitant bone destruc-
tion and ectopic bone formation (especially at the vertebral site)
because of inflammation of tendon/ligament insertions. Thus,
patients with AS experience stiffness of the spine known as anky-
losis, and functional disability (69–71). Inhibition of TNF-α has
substantially advanced the treatment of these two inflammatory
diseases.
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is a chronic disease characterized by joint
inflammation leading to destruction of cartilage and bone (71). In
RA, focal bone loss is due to an excessive bone resorption by OCs
(72). Moreover, bone formation by OBs is greatly impaired at the
erosion site in RA (73). TNF-α plays an important role in the bone
destruction observed in RA patients. TNF inhibitors delay appear-
ance of bone erosion in RA patients with no progression of bone
destruction in responders and possibly to some extend, in non-
responders (9, 74–76). In a murine CIA model, neutralization of
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TNF-α reduced joint pathology, especially when the treatment was
started early after the onset of disease (77). Moreover, simultane-
ous inhibition of TNF-α and IL-17A further improved protection
against joint damage even at the late stages of CIA (78). Mechanis-
tic models of human TNF transgenic mice confirmed that ongoing
TNF-driven inflammation suppresses new bone formation by Wnt
signaling through up-regulation of DKK-1, and then the release
of this inhibition allows new bone formation (45). Furthermore,
several murine autoimmune arthritis models provided evidence
that TNF deficiency reduces disease incidence (79–81).
The pro-inflammatory influence of TNF-α in RA acts at sev-
eral levels. It induces other pro-inflammatory cytokines such as
IL-1 and IL-17 and regulates osteoclastogenesis via several mech-
anisms. TNF-α accelerates cartilage destruction through inducing
the production of matrix metalloproteinases (MMPs) and aggre-
canases (ADAMTSs), which are enzymes that degrade components
of the cartilage extracellular matrix. As an example, in human RA
patients and in the human TNF-α transgenic mouse model, TNF-
α was shown to regulate MMP3 and 13 by the small ubiquitin-like
modifier-1 (SUMO-1) through NF-κB, which led to bone destruc-
tion (82). In addition, TNF-α stimulates OCs maturation both
directly and indirectly by inducing RANKL on synovial fibrob-
lasts, the synovial lining cells, and T-cells in the synovium (52,
83–85). This increased OCs maturation, and in turn, osteoclastic
bone resorption. Moreover, TNF-αpossibly promotes OCs activity
via enhancing oxidative stress. The production of reactive oxygen
species (ROS) by OCs helps accelerate the destruction of calcified
tissue (86). This was confirmed in RA patients using an anti-TNF-
α antibody therapy. In these patients, reduced levels of oxidative
stress markers were associated with the control of joint and bone
damage (87). Thus, TNF-α in RA has a destructive function as net
effect.
ANKYLOSING SPONDYLITIS
Ankylosing spondylitis is the second most common form of
chronic inflammatory arthritis. The unique hallmark of the disease
is pathologic new bone formation (88). AS and related spondy-
loarthritis are characterized by a paradoxical and simultaneous
bone destruction and formation occurring in proximal anatomical
sites. The strongest evidence for a key role of TNF-α in AS patho-
physiology comes from in vivo inhibition of TNF in AS patients.
TNF blockers reduce signs and symptoms of AS, which translates
into better physical function and quality of life. However, little or
no effect on structural remodeling is achieved (89, 90).
In AS, relevant human samples are not readily available even
so TNF expression has been shown at the site of sacroiliitis. Thus,
most observations are only made in rodent models. Recently, mice
that specifically overexpress the transmembrane but not the solu-
ble form of TNF-α, so called tmTNF transgenic mice, developed
clinically spinal abnormalities similar to those in AS (91). These
mice developed pronounced local inflammatory infiltration of the
axial and peripheral joints (88). In sharp contrast with the other
TNF overexpression models, these mice do not develop systemic
inflammation, yet display pronounced axial and peripheral new
bone formation leading to ankylosis (92). This model strongly
argues for a role of tmTNF in the pathogenesis of AS but the
exact molecular mechanisms still need to be elucidated. AS patients
are particularly prone to develop syndesmophytes, a bony growth
originating inside a ligament, and enthesitis, an inflammation at
the sites where tendons or ligaments insert to bone. Therefore,
in these settings, OCs may not be in direct contact with tendon-
derived OBs and TNF-α may exhibit an osteogenic effect there.
This is different from the effect found in whole bone where mas-
sive bone loss is seen. Thus in AS, even with TNF-α inhibition,
ectopic bone formation is still observed, meaning that additional
factors are governing this effect.
OSTEOPOROSIS
Osteoporosis is characterized by a decrease in bone mass and
density leading to bone weakness and prone to fracture. In RA
patients, several studies have shown an increased incidence of
osteoporosis. This could be due to the highly systemic inflam-
matory environment observed in these patients and the use of
glucocorticoid treatment, which can affect bone remodeling (93,
94). Despite ectopic bone formation, AS patients show mas-
sive systemic osteoporosis (95). Among other cytokines, TNF-α
seems to be an important player implicating in osteoporosis via
TNFR1 (96). In RA patients treated with TNF-α inhibitors, con-
trol of bone loss was observed in parallel to that seen on arthritis
levels (76, 97).
CONCLUSION
Tumor necrosis factor-α has an important role in the regulation
of bone homeostasis via activation of complex signaling pathways
leading to gene transcription of several regulators of bone home-
ostasis. The classical view remains that TNF-α is an established
inducer of osteoclastogenesis and inhibitor of osteoblastogenesis.
To add further complexity, it was recently discovered that TNF-
α also possessed osteogenic differentiation effects. Most of these
paradoxical effects were only described in in vitro models and
were concentration- and time-dependent, and cell-type specific.
Despite the fact that TNF-α levels are high in both RA and AS,
the bone dynamics are different. In RA, the dynamics are shifted
toward bone destruction, combined with inhibition of specific
osteogenic genes. In AS, systemic bone destruction is accompa-
nied by ectopic bone formation at sites where OCs and OBs are
disconnected. Future research should focus on the delineation of
the molecular pathways used by this mediator and understand
the conditions affecting and the purpose of this dual role in bone
remodeling.
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